Amlemtuzumab reduces the rate of brain volume loss in rrms patients over 4 years following switch from SC IFNB-1a: CARE-MS extension study

Authors
Category Primary study
JournalNeurology
Year 2017
This article has no abstract
Epistemonikos ID: 0f8fa06e493096a79e0a43209a94631d1717f231
First added on: Feb 08, 2025